MARKET

APTX

APTX

Aptinyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.740
-0.180
-4.59%
After Hours: 3.730 -0.01 -0.27% 16:25 05/29 EDT
OPEN
4.000
PREV CLOSE
3.920
HIGH
4.000
LOW
3.650
VOLUME
281.43K
TURNOVER
--
52 WEEK HIGH
5.25
52 WEEK LOW
1.600
MARKET CAP
170.30M
P/E (TTM)
-2.4187
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average APTX stock price target is 9.80 with a high estimate of 13.00 and a low estimate of 7.00.

EPS

APTX News

More
Is Aptinyx (APTX) Stock Outpacing Its Medical Peers This Year?
Is (APTX) Outperforming Other Medical Stocks This Year?
Zacks · 5d ago
Week 22 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
Seeking Alpha - Article · 6d ago
Aptinyx Inc. (APTX) Moves to Strong Buy: Rationale Behind the Upgrade
Zacks · 05/20 17:00
Some Analysts Just Cut Their Aptinyx Inc. (NASDAQ:APTX) Estimates
Simply Wall St. · 05/20 13:49
Aptinyx's Shares March Higher, Can It Continue?
Zacks · 05/18 13:19
Aptinyx Inc. (NASDAQ:APTX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Simply Wall St. · 05/16 13:44
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/15 00:53
Aptinyx Inc. (APTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks · 05/14 22:15

Industry

Pharmaceuticals
+1.26%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About APTX

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
More

Webull offers kinds of Aptinyx Inc stock information, including NASDAQ:APTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTX stock news, and many more online research tools to help you make informed decisions.